Strides Pharma Science share price gained a percent in the opening trade on January 29 after the company said it received the approval of the United States Food and Drug Administration (USFDA) approval to sell a generic drug for nerve pain.
The company's step‐down wholly owned subsidiary Strides Pharma Global Pte Limited, Singapore has received the nod for Pregabalin capsules, 25 mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg from the US drug regulator.
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Lyrica capsules of Upjohn US. The capsule is used in the treatment of fibromyalgia.
Catch all market action in our live blog
The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 235+ ANDAs have been approved.
The company has set a target to launch a 60 new products over three years in the US.
At 9.43 am, Strides Pharma Science was quoting at Rs 694, up Rs 8.25, or 1.20 percent, on the BSE.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
